Showing results (1-10 of 3,331) with videos related to
Sort By:
Pageof 334
Pharmacoeconomics|October 26, 2022
Health-Related Quality-of-Life Outcomes of Very Preterm or Very Low Birth Weight Adults: Evidence From an Individual Participant Data Meta-AnalysisCorneliu Bolbocean, Sylvia van der Pal, Stef van Buuren, et al.Pharmacoeconomics|October 18, 2022
In a Child's Shoes: Composite Time Trade-Off Valuations for EQ-5D-Y-3L with Different Proxy PerspectivesStefan A Lipman, Brigitte A B Essers, Aureliano P Finch, et al.Pharmacoeconomics|October 13, 2022
Efficiency of the EmERGE Pathway of Care in Five European HIV CentresEduard J Beck, Sundhiya Mandalia, Platon Yfantopoulos, et al.Pharmacoeconomics|December 21, 2014
Cost-effectiveness analysis of onabotulinumtoxinA (BOTOX(®)) for the management of urinary incontinence in adults with neurogenic detrusor overactivity: a UK perspectiveRizwan Hamid, Clara Loveman, Jim Millen, et al.Pharmacoeconomics|October 16, 2014
Does including informal care in economic evaluations matter? A systematic review of inclusion and impact of informal care in cost-effectiveness studiesMarieke Krol, Jocé Papenburg, Job van ExelPharmacoeconomics|November 1, 2015
Cost Effectiveness of Ofatumumab Plus Chlorambucil in First-Line Chronic Lymphocytic Leukaemia in CanadaWilliam Herring, Isobel Pearson, Molly Purser, et al.Pharmacoeconomics|November 9, 2015
Can the EVIDEM Framework Tackle Issues Raised by Evaluating Treatments for Rare Diseases: Analysis of Issues and Policies, and Context-Specific AdaptationMonika Wagner, Hanane Khoury, Jacob Willet, et al.Pharmacoeconomics|June 11, 2016
Impact on the Incremental Cost-Effectiveness Ratio of Using Alternatives to EQ-5D in a Markov Model for Multiple SclerosisMatthijs VersteeghPharmacoeconomics|April 27, 2016
Using Linear Equating to Map PROMIS(®) Global Health Items and the PROMIS-29 V2.0 Profile Measure to the Health Utilities Index Mark 3Ron D Hays, Dennis A Revicki, David Feeny, et al.Pharmacoeconomics|November 28, 2015
What Can We Expect from Value-Based Funding of Medicines? A Retrospective StudyAnthony Harris, Jing Jing Li, Karen YongPageof 334